Entasis Therapeutics
IPO News: Filed S-1: Entasis Therapeutics Files $86.25mm IPO
Entasis Therapeutics

Entasis Therapeutics Holdings

NASDAQ: ETTX

Initial Filing Date: 08/17/18

Size: $86.25

Bookrunners: CS | BMO

Co-Managers: STRH | WEDB

Major Holders: AstraZeneca | Clarus Lifesciences | Nova Holdings | Frazier Life Sciences | Pivotal bioVenture Partners | Sofinna Venture Partners | TPG Biotechnology | Eventide Gilead Fund | Named Executives

Description: Entasis Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Leveraging their targeted-design platform, they have engineered and developed product candidates that target clinically validated mechanisms in order to address antibiotic resistance.

Reference Link: S-1